Vanguards of Health Care by Bloomberg Intelligence

Bloomberg
  • ٥٫٠ (٣)
  • استثمار
  • يتم التحديث كل أسبوعين

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

  1. قبل يوم واحد

    Onward Medical Revives Hope for SCI

    “We thought that the folks would only turn on stimulation when they felt faint or lightheaded, but in fact, they’re using the stimulation the entire waking day because the stimulation is stabilizing their blood pressure, more oxygenation is reaching their brain,” Onward Medical CEO Dave Marver explains in this Vanguards of Health Care podcast episode. Marver sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about Onward and how its developments differ from other companies that utilize brain-computer interfaces (BCI) by connecting BCI technology to its ARC platform to stabilize blood pressure and restore movement of the human body, instead of simply using the patient’s thoughts to control computer functions. Marver also discusses the initiation of its Empower BP Pivotal study to assess the use of its ARC-IM system to address blood-pressure instability after spinal cord injuries (SCI). See omnystudio.com/listener for privacy information.

    ٣٧ من الدقائق

  2. ٢٥ سبتمبر

    Viz.ai Taps Artificial Intelligence to Accelerate Point-of-Care Decisions

    “Doctors don’t want pharma reps to buy them dinner, right? They don’t. They want help in the five minutes that really matter,” Viz.ai’s CEO Chris Mansi and Salesforce’s Frank Defesche explain in this Vanguards of Health Care podcast episode. Mansi and Defesche sit down with Bloomberg Intelligence analyst Matt Henriksson to talk about Viz.ai and its agentic AI platform that connects medical scans and images to the right diagnosis and treatment guidelines. Also tune in to learn how the Viz.ai platform aims to partner with Salesforce’s life-science division to improve pharmaceutical point-of-care workflow while providing more personalized care. See omnystudio.com/listener for privacy information.

    ٤٩ من الدقائق

  3. ١٨ سبتمبر

    Inside Exact Science’s Next Big Bet - One Blood Draw, More than 50 Cancers

    “Our vision as a company is to help eradicate cancer with tests that prevent it, detect it earlier and guide treatment,” says Kevin Conroy, CEO of Exact Sciences. He joins Bloomberg Intelligence analyst Jonathan Palmer on the Vanguards of Health Care podcast to trace Exact’s journey into a cancer-diagnostics leader. From Cologuard’s initial rise to its recently launched Cologuard Plus test, the debut of Cancerguard and expansion into minimal-residual disease (MRD) testing, Conroy shares how science, technology and culture underpin the company’s next decade. See omnystudio.com/listener for privacy information.

    ٤٤ من الدقائق

  4. ١١ سبتمبر

    Moon Surgical Connects with Nvidia to Simplify Surgery with AI

    “We've been working with NVIDIA for a number of years now and we integrated a medical grade, GPU in our commercial product”, CEO Anne Osdoit explains to Bloomberg Intelligence in her description about how AI is being incorporated into Moon Surgical’s surgical robot. In this Vanguards of Health Care podcast episode, Osdoit sits down with BI analyst Matt Henriksson for an in-depth interview on Moon Surgical, the benefits of its Maestro AI-powered surgical platform, and how Maestro can address the current barriers that have kept penetration rates of robotic surgery low. See omnystudio.com/listener for privacy information.

    ٤١ من الدقائق

  5. ٩ سبتمبر

    Legend Biotech's Race to Make Cell Therapy Mainstream

    “Once a scientist, forever a scientist,” says Legend Biotech CEO Ying Huang as he joins Bloomberg Intelligence analyst Sam Fazeli to share his unconventional journey from the lab bench to Wall Street and back to biotech leadership. Dr. Huang explains how a dream led him from equity research to developing one of the most important CAR-T therapies for multiple myeloma. They explore the science behind BCMA targeting, lessons from the pivotal Johnson & Johnson partnership as well as the company’s ambitions in allogeneic and in-vivo therapies. See omnystudio.com/listener for privacy information.

    ٥٦ من الدقائق

  6. ٤ سبتمبر

    AKASA's AI Recovers Millions for Health Systems by Simplifying Complexity

    “American medicine is the best in the world, but the American health-care system is not,” Akasa CEO Malinka Walaliyadde says. In this Vanguards of Health Care episode, Walaliyadde joins Bloomberg Intelligence analyst Jonathan Palmer to explore how Akasa is tackling the chaos of revenue-cycle management with AI. He explains why America’s overlapping payment models create inefficiency, how large-language models read massive patient records in minutes and why custom models built for each health system outperform off-the-shelf AI. They also discuss Akasa’s performance-based business model and the path toward real-time payer-provider communication, as well as the role that grit and conviction play in building a transformative company. See omnystudio.com/listener for privacy information.

    ٥٢ من الدقائق

  7. ٢ سبتمبر

    From the NIH to ModeX, Dr. Elias Zerhouni on Science, Politics, and Innovation

    The worst thing that can happen in health-care and biomedical research is politics getting involved in choosing what research needs to be done for what disease, Dr. Elias Zerhouni tells Bloomberg Intelligence analyst Sam Fazeli, explaining how mixing science and politics weakens innovation and public trust. On this episode of the Vanguards of Health Care podcast, Zerhouni, a former NIH director and vice chairman of OPKO Health, unpacks his new book Disease Knows No Politics, warns against cutting US research funding and explains why immigration is vital for scientific leadership. He also dives into OPKO and ModeX’s cutting-edge work on multivalent vaccines and multi-specific antibodies that could change the treatment landscape.   See omnystudio.com/listener for privacy information.

    ٥٠ من الدقائق

  8. ٢٨ أغسطس

    Zimmer Biomet’s Ivan Tornos is Investing in the Next Chapter of Orthopedics with Arnold

    “We are reinventing ourselves. We don’t want to be just a legacy orthopedic company and I think we’re driving with the same enthusiasm as Arnold Schwarzenegger,” Zimmer Biomet Chairman, President and CEO Ivan Tornos tells Bloomberg Intelligence. In this Vanguards of Health Care episode, Tornos sits down with BI analyst Matt Henriksson for an in-depth interview about Zimmer Biomet and the strategic initiatives made through internal developments and key acquisitions, including Paragon 28 and Monogram, to accelerate its weighted average market growth rate (WAMGR). He also discusses the current orthopedic landscape and the opportunities arising from the shift to the ambulatory surgical center (ASC) setting, as well as his relationship with Arnold Schwarzenegger as Chief Movement Officer. See omnystudio.com/listener for privacy information.

    ٣٨ من الدقائق
مشاهدة الكل (١٠٩)

التقييمات والمراجعات

٥
من ٥
‫٣ من التقييمات‬

حول

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

المعلومات

قد يعجبك أيضًا